Endothelial functions in Behçet’s disease

Kayıkçıoğlu, Meral; Aksu, Kenan; Hasdemir, Can; Keser, Gökhan; Turgan, Nevbahar; Kültürsay, Hakan; Doğanavşargil, Eker

doi:10.1007/s00296-005-0590-1

Cited by 44 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Exclusion criteria were reported in 13 studies, 4 of them specified that patients taking drugs interfering with hcy levels were excluded. Thus, 4 studies were considered of high quality, 4,24,25,28 whereas the other 12 were considered of low quality. 8,12,26,27,29 -36 Hyperhomocysteinemia Eight studies, 4,12,26,27,30,32,35,36 for a total of 166 patients with thrombosis and 318 patients without thrombosis, were included in the metaanalysis.…”

Section: Study Qualitymentioning

confidence: 99%

“…Eleven studies, 4,8,12,24,25,[27][28][29][30]32,36 for a total of 236 patients with thrombosis and 518 patients without thrombosis, were included in the metaanalysis. In these patients, mean levels of hcy were significantly higher in patients with thrombosis compared with patients without thrombosis (mean difference 3.30 mol/L; 95% CI 2.09 to 4.51; Figure 3), again suggesting an association between the high levels of hcy and the development of thrombosis.…”

Section: Mean Levels Of Homocysteinementioning

confidence: 99%

See 1 more Smart Citation

Homocysteine in Vascular Behçet Disease

Regina

Orlandini

Prisco

et al. 2010

ATVB

View full text Add to dashboard Cite

Objective-Behçet disease (BD) is a vasculitis of unknown etiology, characterized by oral or genital aphtosis and uveitis.Homocysteine (hcy) is an independent risk factor for venous and arterial thrombosis. The association between hyperhomocysteinemia and thrombosis has been investigated in some studies in BD patients. However, information on this association is based only on the results of small studies with conflicting results. To overcome such limitations, we performed a metaanalysis comparing the plasma levels of hcy in BD patients with and without history of thrombosis. Methods and Results-We searched for all published studies using the Medline and Embase databases. Two reviewers performed study selection independently. Studies were included if hcy was measured in adult BD patients with and without thrombosis. Two reviewers independently extracted data on study and population characteristics. The mean value of hcy in BD patients and the presence of hyperhomocysteinemia in patients with and without thrombosis were collected. Association between thrombosis and hyperhomocysteinemia, and the mean difference of hcy levels in BD patients with and without thrombosis were calculated. Sixteen studies, for a total of 979 patients, were included. Hyperhomocysteinemia was more prevalent in patients with thrombosis than in those without (odds ratio 3.14; 95% CI 1.26 to 7.80) Mean levels of hcy were significantly higher in patients with thrombosis in comparison with patients without (mean difference 3.30 mol/L; 95% CI 2.09 to 4.51). This high prevalence of thromboses, known since the 1950s, 3 promoted several studies aimed at investigating their pathobiology. Endothelial injury itself, common to other vasculitis, cannot clearly account for thrombosis development, so a hypercoagulable state was early hypothesized and investigated. 4 In the last several years, several inherited or acquired factors causing hypercoagulability have been studied in patients with venous and arterial thromboembolic events. 5-7 These thrombophilic factors have also been studied in patients with BD with a history of thrombosis, and conflicting results were obtained. 8 -11 Recently, Ricart et al performed a metaanalysis evaluating the role of FV Leiden, prothrombin G2021A mutation, and the homozygous 677TT mutation of the methyltetrahydrofolate reductase as risk factors for venous thrombosis in BD patients. 12 In this study, FV Leiden and G2021A prothrombin mutation were found to increase the risk of thrombosis in these patients, whereas 677TT mutation of methyltetrahydrofolate reductase did not. Conclusion-OurThese findings are consistent with the results of recent studies performed in general populations in which the presence of 677TT mutation of methyltetrahydrofolate reductase is not a risk factor for venous thromboembolism in the absence of hyperhomocysteinemia. 13 On the other hand, in the general population, increased levels of homocysteine (hcy) have been reported to be an independent risk factor for venous thromboembolism in addition to c...

show abstract

Section: Study Qualitymentioning

confidence: 99%

Section: Mean Levels Of Homocysteinementioning

confidence: 99%

Homocysteine in Vascular Behçet Disease

Regina

Orlandini

Prisco

et al. 2010

ATVB

View full text Add to dashboard Cite

show abstract

“…Inflammation materials such as polymorphonuclear leukocytes (PMNs) are activated in RAS,68, 69, 70, 71 and PMNs exhibit increased motility and enhanced adhesion to endothelial cells in vitro 72, 73. Endothelial dysfunction is typical in patients with RAS and BD 74, 75, 76, 77. In such patients, endothelium‐dependent flow‐mediated dilation is reduced and endothelial activation in affected blood vessels mediates vascular inflammation and thrombosis 75, 76.…”

Section: Discussionmentioning

confidence: 99%

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

et al. 2018

View full text Add to dashboard Cite

BackgroundRecurrent aphthous stomatitis (RAS) is considered a prophase symptom in patients with specific cancers. This study assessed the association between RAS and subsequent onset of cancer based on a nationwide population‐based database in Taiwan.Materials and MethodsWe selected study participants from the National Health Insurance Research Database from January 2000 to December 2008. Patients in the non‐RAS cohort were matched to case study patients at a 1:1 ratio through frequency matching. All participants were followed up for at least 5 years, and those who received cancer diagnoses during follow‐up were identified.ResultsAmong 52 307 patients with and 52 304 patients without RAS, the combined hazard ratio (HR) of all subsequent cancer cases was 1.3 (95% confidence interval [CI]: 1.25‐1.35, P = 0). RAS diagnosis was associated with risk for cancers of the head and neck (aHR = 2, 95% CI: 1.8‐2.3), colon (aHR = 1.2, 95% CI: 1.1‐1.4), liver (aHR = 1.1, 95% CI: 1‐1.3), pancreas (aHR = 1.4, 95% CI: 1.1‐1.7), skin (aHR = 1.4, 95% CI: 1.2‐1.7), breast (aHR = 1.2, 95% CI: 1.1‐1.4), and prostate (aHR = 1.5, 95% CI: 1.3‐1.8), as well as hematologic cancers (aHR = 1.6, 95% CI: 1.3‐1.9). A higher risk was observed for male patients (aHR = 1.35, 95% CI: 1.28‐1.42) than for female patients (aHR = 1.25, 95% CI: 1.18‐1.31) with RAS.Conclusions RAS was associated with specific cancers. Susceptible RAS patients should be screened for specific cancers.

show abstract

“…One of the main findings of the present study is that short-term treatment with nebivolol improves impaired endothelial vasodilator function. Several case-control studies have observed an association between vascular involvement and decreased brachial FMD and increased arterial stiffness in patients with BD (10,(32)(33)(34). Reduced NO production is the one of the possible mechanisms for endothelial dysfunction in BD (11), and the decreased NO production may play a critical role in the impairment of FMD.…”

Section: Discussionmentioning

confidence: 99%

Effect of nebivolol on endothelial dysfunction in patients with Behçet’s disease; a prospective single-arm controlled study

Akkaya¹,

Şahin²,

Borlu³

et al. 2012

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: Behçet's disease (BD) is a systemic vasculitis, capable of involving all types of vessels. Endothelial dysfunction (ED) has been previously documented in BD. Previous studies showed that nebivolol might improve endothelial functions in endothelial dysfunction. The aim of our study is to assess the effects of nebivolol on endothelial dysfunction in patients with Behçet's disease. Methods: This study was designed as prospective single-arm controlled study. We prospectively studied 35 Behçet's patients who were diagnosed according to the International Study Group criteria. Patients received 5 mg nebivolol per day for 3 months. Endothelial dysfunction was evaluated by brachial artery flow-mediated dilatation (FMD) method using high-resolution vascular ultrasound device at baseline and after for 3-month therapy. The paired samples t test, Wilcoxon test, Pearson, Spearman correlation analyses were used for statistical analysis. Results: A significant improvement was observed in FMD after therapy period (4.23±1.19 vs 7.95±2.21%, p<0.001). The correlation analysis showed a negative correlation between post-treatment high-sensitive C-reactive protein and FMD (r=-0.435, p=0.009). No adverse effects were observed in treatment period. Conclusion: Nebivolol improved endothelial dysfunction in Behçet's patients. However, further comprehensive studies are needed to determine the long-term effects of nebivolol. (Anadolu Kardiyol Derg 2013; 13: 115-20

show abstract

Endothelial functions in Behçet’s disease

Cited by 44 publications

References 16 publications

Homocysteine in Vascular Behçet Disease

Homocysteine in Vascular Behçet Disease

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

Effect of nebivolol on endothelial dysfunction in patients with Behçet’s disease; a prospective single-arm controlled study

Contact Info

Product

Resources

About